Review: Omalizumab reduces asthma exacerbations and daily steroid use

Abstract

TherapeuticsJanuary 1, 2004Review: Omalizumab reduces asthma exacerbations and daily steroid useFrank Thien, MD, FRACP, FCCPFrank Thien, MD, FRACP, FCCPAlfred Hospital & Monash University, Melbourne, Victoria, Australia (F.T.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2004-140-1-013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinkedInRedditEmail Source CitationWalker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma. Cochrane Database Syst Rev. 2003;(3):CD003559. https://pubmed.ncbi.nlm.nih.gov/12917972Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111:278-84. [PMID: 12589345] Google Scholar2 Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90. [PMID: 11496232] Google Scholar Author, Article, and Disclosure InformationAffiliations: Alfred Hospital & Monash University, Melbourne, Victoria, Australia (F.T.) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails January 1, 2004Volume 140, Issue 1Page: 13KeywordsAllergensAllergy and immunologyAntibodiesAsthmaBasophilsBiotechnologyChildrenFallsImmune systemInformation storage and retrievalLungsMast cellsMonoclonal antibodiesNeurologyQuality of lifeRoutes of administrationSteroid therapy ePublished: 9 March 2020 Issue Published: January 1, 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...